Brief: Nanjing Leads Biolabs Says LBL-024 (Opamtistomig, Pd-L1/4-1Bb Bispecific Antibody) Granted Fast Track Designation By U.S. FDA
14/01/2026 15:29
Jan 14 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK: LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY U.S. FDA Further company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer